We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · July 01, 2021

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC

Journal of Thoracic Oncology

 

Additional Info

Journal of Thoracic Oncology
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
J Thorac Oncol 2021 May 25;[EPub Ahead of Print], C Zhou, L Wu, Y Fan, Z Wang, L Liu, G Chen, L Zhang, D Huang, S Cang, Z Yang, J Zhou, C Zhou, B Li, J Li, M Fan, J Cui, Y Li, H Zhao, J Fang, J Xue, C Hu, P Sun, Y Du, H Zhou, S Wang, W Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading